Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for pediatric patients with hematologic malignancies. Human leukocyte antigen (HLA)-matched sibling donors (MSDs) are considered the optimal source for stem cell transplantation; however, up to 70% of patients lack an MSD. This disparity is particularly pronounced among racial and ethnic minorities, who face challenges in identifying matched unrelated donors (MUDs). Haploidentical (haplo) donors are nearly universally available and have become viable alternatives with post-transplant cyclophosphamide (PT-CY) improving immune reconstitution and reducing graft-versus-host disease (GvHD). While adult studies have demonstrated comparable outcomes between haplo-HCT and MSD-HCT, pediatric data remain limited, especially in racial and ethnic minority populations. This study aimed to compare the clinical outcomes of myeloablative conditioning (MAC) haplo-HCT versus MSD-HCT in pediatric and adolescent/young adult (AYA) patients with hematologic malignancies, predominantly from Hispanic and other minority backgrounds. A retrospective single-center analysis was conducted on 72 pediatric and AYA patients (0-28 years) with hematologic malignancies who underwent MAC followed by either T-cell-replete haplo-HCT (n=43) or MSD-HCT (n=29) between October 2013 and March 2025. Conditioning regimens included total body irradiation (TBI)- or busulfan-based protocols. GvHD prophylaxis consisted of PT-CY ± bendamustine (PT-BEN) with tacrolimus-mycophenolate mofetil (haplo-HCT) or methotrexate-cyclosporine (MSD-HCT). At a median follow-up of 39.4 months (MSD-HCT) and 48.7 months (haplo-HCT), OS was 74.5% for MSD-HCT and 70.1% for haplo-HCT (P=0.89), while LFS was 70.6% and 67.8%, respectively (P=0.87). Relapse rates (26.8% vs. 23.0%; P=0.49) and NRM (13.1% vs. 9.8%; P=0.95) were comparable between groups. The cumulative incidence of grade III-IV acute GvHD was higher, though not statistically significant, in haplo-HCT (19.4% vs. 7.3%; P=0.17), whereas chronic GvHD rates were 35.9% (MSD) vs. 23.9% (haplo) (P=0.25). GvHD-free, relapse-free survival (GRFS) was 60.1% for MSD-HCT versus 54.1% for haplo-HCT (P=0.83). Haplo-HCT recipients had higher rates of cytomegalovirus (CMV) reactivation requiring therapy (40% vs. 7%; P=0.002). Donor age was independently associated with increased chronic GvHD risk in multivariable analyses. In this predominantly Hispanic pediatric and AYA cohort, haplo-HCT with PT-CY achieved survival, relapse, and NRM outcomes comparable to MSD-HCT, supporting its role as a practical alternative when MSDs are unavailable. Although haplo-HCT was associated with a higher risk of CMV reactivation and a non-significant trend toward increased severe acute GvHD, overall GvHD rates were manageable. Donor age emerged as a key predictor of chronic GvHD, underscoring its importance in haploidentical donor selection. These findings highlight haplo-HCT as an effective and accessible transplant option for minority populations with limited donor availability.
Short-term activation of natural killer (NK) cells with interleukin-12 (IL-12), IL-15, and IL-18 (IL-12/15/18) gives rise to cytokine-induced memory-like (CIML) NK cells after adoptive transfer, which exhibit enhanced antitumor activity, proliferation, and persistence. Clinical trials in high-risk leukemia have shown encouraging results, yet significant challenges remain, particularly the limited durability of cytotoxicity and the failure to achieve sustained remission. We recently demonstrated that acute exercise induces a threefold to fourfold increase in circulating NK cells enriched for gene programs and surface proteins linked to antitumor activity. Here, we tested whether exercise-mobilized NK cells could improve the function of IL-12/15/18–activated NK (aNK) cells in vitro and CIML NK cells in vivo. Eighteen healthy donors performed 20 minutes of graded cycling up to 80% maximal oxygen uptake, with blood collected at rest and during exercise. NK cells purified from rest and exercise (NK-X) were cultured overnight with IL-15 (NK or NK-X) or IL-12/15/18 (aNK or aNK-X). End points included in vitro cytotoxicity and tumor control in leukemia-bearing xenogeneic mice. aNK-X cells exhibited stronger cytotoxicity against 2 myeloid leukemia cell lines than aNK cells from the same donors, accompanied by increased interferon gamma production, enhanced degranulation, and an enriched phenotype (higher NKG2A-/NKG2D+, CD57+, CD16+). Notably, NK-Xs displayed greater cytotoxic activity than NKs and were comparable with aNK cells, although aNK-X cells outperformed both. In mice, CIML NK-X cells combined with exercise-mobilized donor lymphocyte infusion (DLI-X) prolonged engraftment, delayed tumor progression, and extended survival relative to CIML NK cells combined with standard DLI. These findings demonstrate that exercise-induced NK cell mobilization combined with cytokine preactivation yields an adoptive cell therapy product with superior antileukemic activity. This trial was registered at www.ClinicalTrials.gov as NCT06643221.
Background/Objectives: Bendamustine (BEN) combined with rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formulation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we investigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 inhibitor Venetoclax (VEN) and/or the oral BTKi Acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. Methods: We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. For the in vivo studies, all treatments were administered via oral gavage in xenograft mouse models. Therapeutic efficacy was evaluated by monitoring tumor growth and survival. Results: BEN induced significant cytotoxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrated limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Conclusions: Our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.
Cytokine-induced memory-like natural killer cells (CIMLNK) represent a novel form of adoptive cellular therapy that is easy to manufacture and readily available. These cells are generated after overnight stimulation of purified natural killer (NK) cells with interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18). While CIMLNK has demonstrated efficacy in patients with relapsed or refractory acute myeloid leukemia (AML), its potential application in B-cell acute lymphoblastic leukemia (B-ALL) remains unclear. Tafasitamab (TAFA), a monoclonal antibody (mAb) directed against CD19, a surface antigen expressed on B-ALL cells, has been developed to augment anti-tumor efficacy through antibody-dependent cellular cytotoxicity (ADCC), a mechanism predominantly mediated by NK cells. Consequently, we sought to assess the susceptibility of B-ALL to the combination of CIMLNK and TAFA using three B-ALL cell lines: NALM6, SUP-B15, and RS4;11. The addition of TAFA significantly augmented the cytotoxic activity, degranulation capacity, and IFN-γ production of CIMLNK. TAFA-induced ADCC was found to be dose-dependent and was abolished after CD16 blockade. Furthermore, TAFA-mediated effects against NALM6 and SUP-B15 were more pronounced in CIMLNK compared to unstimulated NK cells. In vivo, the combination of CIMLNK and TAFA led to a more pronounced survival benefit in leukemia-bearing mice. In summary, our findings suggest that this combination holds promise as a potential alternative treatment option for patients with relapsed refractory B-ALL.
12 June 2026 in Journal for ImmunoTherapy of Cancer
Background: Relapse and graft-versus-host disease (GvHD) remain primary causes of treatment failure in patients with B-cell acute lymphoblastic leukemia (B-ALL) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While abatacept (ABATA) effectively mitigates GvHD via CD28-costimulation blockade, there is significant concern that it concurrently diminishes graft-versus-leukemia (GvL) effects, potentially leading to higher relapse rates. We investigated whether blinatumomab (BLINA) retains antileukemic efficacy in the presence of ABATA using in vitro assays and humanized NOD.Cg-Prkdc scid Il2rg tm1Wjl Tg(IL15)1Sz/SzJ (NSG-IL15) and NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mouse models. Methods: In vitro and ex vivo flow cytometry-based cytotoxicity, degranulation (CD107a), cytokine production (interferon (IFN)-γ), and activation-marker (CD25, CD69, CD137, OX40) assays were performed using healthy donor peripheral blood mononuclear cells (PBMCs) (pretreated±ABATA) against leukemia or lymphoma cell lines (RS4;11, NALM-6, and JEKO-1) in the presence or not of BLINA. In vivo human PBMC-reconstituted NSG-IL-15 mice bearing RS4;11 B-ALL xenografts were treated with vehicle, monotherapy (BLINA or ABATA), or combination therapy. Leukemia burden and immune reconstitution were assessed through week 4; GvHD scores and overall survival were monitored longitudinally. Results: ABATA did not impair BLINA-mediated cytotoxicity across multiple effector-to-target ratios against any of the cell lines, nor did it reduce BLINA-induced degranulation, IFN-γ production, or activation marker expression. In vivo, BLINA monotherapy significantly reduced leukemia burden, but resulted in early mortality due to severe GvHD. Conversely, ABATA markedly reduced GvHD severity. The combination of BLINA and ABATA preserved potent antileukemic efficacy while significantly extending median survival by 35 days compared with tumor controls (p<0.0001). Although ABATA attenuated T-cell expansion and differentiation, BLINA-driven cytotoxic function was maintained, even after prolonged in vivo exposure to cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA-4-Ig). Conclusion: These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.
Bendamustine (BEN) combined with Rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL). Meanwhile, novel targeted therapies such as Bruton tyrosine kinase inhibitors (BTKis) are increasingly used in the treatment of relapsed/refractory (R/R) MCL. We recently reported that a novel oral formu-lation of BEN exhibits comparable efficacy to the intravenous counterpart. In this study, we in-vestigated the efficacy of oral BEN administered alone or in combination with the oral BCL-2 in-hibitor Venetoclax (VEN) and/or the oral BTKi acalabrutinib (ACAL), against two human MCL cell lines (Jeko-1 and Z-138) representative of the R/R disease subtype. We performed in vitro analyses using MTS viability and Annexin V/PI apoptosis assays. BEN induced significant cyto-toxicity in both cell lines at low, clinically relevant concentrations. In contrast, VEN demonstrat-ed limited efficacy as monotherapy, with Z-138 showing sensitivity only at high doses. However, combining BEN with VEN with or without ACAL, enhanced apoptosis and cytotoxicity, with more pronounced effects in Z-138. In vivo, oral BEN significantly reduced tumor growth and prolonged survival in both xenograft models. In the Z-138 model, the addition of VEN ± ACAL further improved survival outcomes. Overall, our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.